{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T23:27:05Z","timestamp":1793662025979,"version":"4.5.1"},"reference-count":177,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T00:00:00Z","timestamp":1736812800000},"content-version":"vor","delay-in-days":13,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003669","name":"Korea Centers for Disease Control and Prevention","doi-asserted-by":"publisher","award":["6634-325-320-01"],"award-info":[{"award-number":["6634-325-320-01"]}],"id":[{"id":"10.13039\/501100003669","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF- 2021R1A2C2006961"],"award-info":[{"award-number":["NRF- 2021R1A2C2006961"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018688","name":"Korea Disease Control and Prevention Agency","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018688","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003653","name":"Korea National Institute of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003653","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003625","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["HI23C0392"],"award-info":[{"award-number":["HI23C0392"]}],"id":[{"id":"10.13039\/501100003625","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.heliyon.2025.e41980","type":"journal-article","created":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T17:10:35Z","timestamp":1736961035000},"page":"e41980","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":56,"title":["SARS-CoV-2 drug resistance and therapeutic approaches"],"prefix":"10.1016","volume":"11","author":[{"given":"Sania","family":"Batool","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santosh","family":"Chokkakula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju Hwan","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun Hee","family":"Baek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min-Suk","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.heliyon.2025.e41980_bib1","first-page":"157","article-title":"WHO declares COVID-19 a pandemic","volume":"91","author":"Cucinotta","year":"2020","journal-title":"Acta Bio Medica Atenei Parmensis"},{"key":"10.1016\/j.heliyon.2025.e41980_bib2","author":"Doucleff"},{"key":"10.1016\/j.heliyon.2025.e41980_bib3","series-title":"Emergency Committee on the COVID-19 Pandemic","article-title":"\u201cStatement on the fifteenth meeting of the IHR","year":"2005"},{"issue":"7798","key":"10.1016\/j.heliyon.2025.e41980_bib4","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","article-title":"A pneumonia outbreak associated with a new coronavirus of probable bat origin","volume":"579","author":"Zhou","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.heliyon.2025.e41980_bib5","doi-asserted-by":"crossref","DOI":"10.3389\/fviro.2022.875213","article-title":"SARS-CoV-2 and the missing link of intermediate hosts in viral emergence - what we can learn from other betacoronaviruses","volume":"2","author":"Schindell","year":"2022","journal-title":"Front. Virol."},{"issue":"14","key":"10.1016\/j.heliyon.2025.e41980_bib6","doi-asserted-by":"crossref","first-page":"7790","DOI":"10.1128\/JVI.01244-13","article-title":"Commentary: Middle East respiratory syndrome coronavirus (MERS-CoV): announcement of the coronavirus study group","volume":"87","author":"De Groot","year":"2013","journal-title":"J. Virol."},{"issue":"1","key":"10.1016\/j.heliyon.2025.e41980_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1203\/01.PDR.0000129184.87042.FC","article-title":"SARS: the first pandemic of the 21st century","volume":"56","author":"Cherry","year":"2004","journal-title":"Pediatr. Res."},{"issue":"9","key":"10.1016\/j.heliyon.2025.e41980_bib8","doi-asserted-by":"crossref","first-page":"e683","DOI":"10.1002\/iid3.683","article-title":"Missense mutations in spike protein of SARS\u2010CoV\u20102 delta variant contribute to the alteration in viral structure and interaction with hACE2 receptor","volume":"10","author":"Mahmood","year":"2022","journal-title":"Immun Inflamm Dis"},{"key":"10.1016\/j.heliyon.2025.e41980_bib9","first-page":"1","article-title":"Omicron variant evolution on vaccines and monoclonal antibodies","author":"Sabbatucci","year":"2023","journal-title":"Inflammopharmacology"},{"issue":"1","key":"10.1016\/j.heliyon.2025.e41980_bib10","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1038\/s41467-023-36561-6","article-title":"Resistance of Omicron subvariants BA.2.75.2, BA.4.6, and BQ.1.1 to neutralizing antibodies","volume":"14","author":"Planas","year":"2023","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.heliyon.2025.e41980_bib11","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S1473-3099(22)00733-2","article-title":"Omicron sublineage BQ.1.1 resistance to monoclonal antibodies","volume":"23","author":"Arora","year":"2023","journal-title":"Lancet Infect. Dis."},{"issue":"2","key":"10.1016\/j.heliyon.2025.e41980_bib12","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41579-022-00809-7","article-title":"SARS-CoV-2 variant evasion of monoclonal antibodies based on in vitro studies","volume":"21","author":"Cox","year":"2023","journal-title":"Nat. Rev. Microbiol."},{"issue":"8","key":"10.1016\/j.heliyon.2025.e41980_bib14","doi-asserted-by":"crossref","first-page":"e675","DOI":"10.1002\/mco2.675","article-title":"The rising SARS-CoV-2 JN.1 variant: evolution, infectivity, immune escape, and response strategies","volume":"5","author":"Lu","year":"2024","journal-title":"MedComm"},{"issue":"3","key":"10.1016\/j.heliyon.2025.e41980_bib15","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.chom.2021.01.014","article-title":"Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization","volume":"29","author":"Liu","year":"2021","journal-title":"Cell Host Microbe"},{"issue":"1","key":"10.1016\/j.heliyon.2025.e41980_bib16","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1186\/s12879-021-06902-1","article-title":"Emergence of SARS-CoV-2 resistance mutations in a patient who received anti-SARS-COV2 spike protein monoclonal antibodies: a case report","volume":"21","author":"Fenaux","year":"2021","journal-title":"BMC Infect. Dis."},{"key":"10.1016\/j.heliyon.2025.e41980_bib17","unstructured":"O. of the Commissioner, \u201cCoronavirus (COVID-19) Update: FDA Limits Use of Certain Monoclonal Antibodies to Treat COVID-19 Due to the Omicron Variant,\u201d FDA. Accessed: November. 26, 2023. [Online]. Available: https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-limits-use-certain-monoclonal-antibodies-treat-covid-19-due-omicron."},{"key":"10.1016\/j.heliyon.2025.e41980_bib18","unstructured":"Monoclonal Antibody Therapy Was Effective for Earlier Variants of COVID-19,\u201d Froedtert & the Medical College of Wisconsin. Accessed: November. 26, 2023. [Online]. Available: https:\/\/www.froedtert.com\/stories\/monoclonal-antibody-therapy-was-effective-earlier-variants-covid-19."},{"issue":"14","key":"10.1016\/j.heliyon.2025.e41980_bib19","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01031-17","article-title":"Complexities of viral mutation rates","volume":"92","author":"Peck","year":"2018","journal-title":"J. Virol."},{"issue":"4","key":"10.1016\/j.heliyon.2025.e41980_bib20","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/j.cell.2020.03.045","article-title":"Structural and functional basis of SARS-CoV-2 entry by using human ACE2","volume":"181","author":"Wang","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.heliyon.2025.e41980_bib21","doi-asserted-by":"crossref","DOI":"10.3389\/fviro.2021.815388","article-title":"SARS-CoV-2 and the host cell: a tale of interactions","volume":"1","author":"Pizzato","year":"2022","journal-title":"Front.Virol."},{"issue":"3","key":"10.1016\/j.heliyon.2025.e41980_bib22","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41579-020-00468-6","article-title":"Coronavirus biology and replication: implications for SARS-CoV-2","volume":"19","author":"V\u2019kovski","year":"2021","journal-title":"Nat. Rev. Microbiol."},{"issue":"1","key":"10.1016\/j.heliyon.2025.e41980_bib23","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1093\/emph\/eoac010","article-title":"Mutation rate of SARS-CoV-2 and emergence of mutators during experimental evolution","volume":"10","author":"Amicone","year":"2022","journal-title":"Evolution, Medicine, and Public Health"},{"issue":"19","key":"10.1016\/j.heliyon.2025.e41980_bib24","doi-asserted-by":"crossref","first-page":"9733","DOI":"10.1128\/JVI.00694-10","article-title":"Viral mutation rates","volume":"84","author":"Sanju\u00e1n","year":"2010","journal-title":"J. Virol."},{"issue":"1","key":"10.1016\/j.heliyon.2025.e41980_bib25","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/s12967-023-03996-w","article-title":"Global landscape of SARS-CoV-2 mutations and conserved regions","volume":"21","author":"Abbasian","year":"2023","journal-title":"J. Transl. Med."},{"issue":"4","key":"10.1016\/j.heliyon.2025.e41980_bib26","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1089\/aid.1996.12.307","article-title":"Forward mutation rate of human immunodeficiency virus type 1 in a T lymphoid cell line","volume":"12","author":"Mansky","year":"1996","journal-title":"AIDS Res. Hum. Retrovir."},{"issue":"5","key":"10.1016\/j.heliyon.2025.e41980_bib27","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1086\/322801","article-title":"Ferrets as a transmission model for influenza: sequence changes in HA1 of type A (H3N2) virus","volume":"184","author":"Herlocher","year":"2001","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.heliyon.2025.e41980_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.meegid.2020.104351","article-title":"Emergence of genomic diversity and recurrent mutations in SARS-CoV-2","volume":"83","author":"Van Dorp","year":"2020","journal-title":"Infect. Genet. Evol."},{"issue":"4","key":"10.1016\/j.heliyon.2025.e41980_bib29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0250780","article-title":"Risk of rapid evolutionary escape from biomedical interventions targeting SARS-CoV-2 spike protein","volume":"16","author":"Van Egeren","year":"2021","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.heliyon.2025.e41980_bib30","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1002\/jmv.25701","article-title":"Transmission dynamics and evolutionary history of 2019-nCoV","volume":"92","author":"Li","year":"2020","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.heliyon.2025.e41980_bib31","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.ijid.2020.11.190","article-title":"Evolution and genetic diversity of SARS-CoV-2 in Africa using whole genome sequences","volume":"103","author":"Motayo","year":"2021","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.heliyon.2025.e41980_bib33","unstructured":"O. of the Commissioner, \u201cFDA Approves First Oral Antiviral for Treatment of COVID-19 in Adults,\u201d FDA. Accessed: November. 20, 2023. [Online]. Available: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-oral-antiviral-treatment-covid-19-adults."},{"issue":"15","key":"10.1016\/j.heliyon.2025.e41980_bib34","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1056\/NEJMoa2118542","article-title":"Oral nirmatrelvir for high-risk, nonhospitalized adults with covid-19","volume":"386","author":"Hammond","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.heliyon.2025.e41980_bib35","unstructured":"\u201cBroad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses | Sci. Transl. Med.\u201d Accessed: November. 20, 2023. [Online]. Available: https:\/\/www.science.org\/doi\/full\/10.1126\/scitranslmed.aal3653."},{"issue":"3","key":"10.1016\/j.heliyon.2025.e41980_bib36","doi-asserted-by":"crossref","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Res."},{"issue":"19","key":"10.1016\/j.heliyon.2025.e41980_bib37","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the treatment of covid-19 \u2014 final report","volume":"383","author":"Beigel","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.heliyon.2025.e41980_bib38","unstructured":"Emergency Use Authorization (EUA) for Remdesivir, an Unapproved Product Center for Drug Evaluation and Research (CDER) Review\u201d."},{"key":"10.1016\/j.heliyon.2025.e41980_bib41","unstructured":"\u201cSARS-CoV-2 infection is effectively treated and prevented by EIDD-2801 | Nature.\u201d Accessed: November. 21, 2023. [Online]. Available: https:\/\/www.nature.com\/articles\/s41586-021-03312-w."},{"issue":"12","key":"10.1016\/j.heliyon.2025.e41980_bib42","doi-asserted-by":"crossref","DOI":"10.1038\/nm.3985","article-title":"A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence","volume":"21","author":"Menachery","year":"2015","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.heliyon.2025.e41980_bib43","doi-asserted-by":"crossref","DOI":"10.1038\/s41564-020-00835-2","article-title":"Therapeutically administered ribonucleoside analogue MK-4482\/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets","volume":"6","author":"Cox","year":"2021","journal-title":"Nat Microbiol"},{"key":"10.1016\/j.heliyon.2025.e41980_bib45","doi-asserted-by":"crossref","unstructured":"I. I. William A. Fischer et al., \u201cA phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus,\u201d Sci. Transl. Med., vol. 14, no. 628, doi: 10.1126\/scitranslmed.abl7430.","DOI":"10.1126\/scitranslmed.abl7430"},{"issue":"10","key":"10.1016\/j.heliyon.2025.e41980_bib46","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00697-22","article-title":"A randomized phase 2\/3 study of ensitrelvir, a novel oral SARS-CoV-2 3C-like protease inhibitor, in Japanese patients with mild-to-moderate COVID-19 or asymptomatic SARS-CoV-2 infection: results of the phase 2a part","volume":"66","author":"Mukae","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"issue":"9","key":"10.1016\/j.heliyon.2025.e41980_bib47","doi-asserted-by":"crossref","first-page":"6499","DOI":"10.1021\/acs.jmedchem.2c00117","article-title":"Discovery of S-217622, a noncovalent oral SARS-CoV-2 3CL protease inhibitor clinical candidate for treating COVID-19","volume":"65","author":"Unoh","year":"2022","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.heliyon.2025.e41980_bib48","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/s42003-023-05071-y","article-title":"Molecular mechanism of ensitrelvir inhibiting SARS-CoV-2 main protease and its variants","volume":"6","author":"Lin","year":"2023","journal-title":"Commun. Biol."},{"issue":"7","key":"10.1016\/j.heliyon.2025.e41980_bib49","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2183\/pjab.93.027","article-title":"Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase","volume":"93","author":"Furuta","year":"2017","journal-title":"Proc. Jpn. Acad. Ser. B Phys. Biol. Sci."},{"issue":"10","key":"10.1016\/j.heliyon.2025.e41980_bib51","first-page":"1192","article-title":"Experimental treatment with favipiravir for COVID-19: an open-label control study","volume":"6","author":"Cai","year":"2020","journal-title":"Engineering (Beijing)"},{"issue":"4","key":"10.1016\/j.heliyon.2025.e41980_bib52","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.mjafi.2020.08.004","article-title":"Favipiravir: a new and emerging antiviral option in COVID-19","volume":"76","author":"Agrawal","year":"2020","journal-title":"Med. J. Armed Forces India"},{"key":"10.1016\/j.heliyon.2025.e41980_bib54","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ijid.2020.11.142","article-title":"Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: a randomized, comparative, open-label, multicenter, phase 3 clinical trial","volume":"103","author":"Udwadia","year":"2021","journal-title":"Int. J. Infect. Dis."},{"issue":"9","key":"10.1016\/j.heliyon.2025.e41980_bib55","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1021\/jm801595c","article-title":"The design, synthesis, and antiviral activity of monofluoro and difluoro analogues of 4\u2032-azidocytidine against hepatitis C virus replication: the discovery of 4\u2032-Azido-2\u2032-deoxy-2\u2032-fluorocytidine and 4\u2032-Azido-2\u2032-dideoxy-2\u2032,2\u2032-difluorocytidine","volume":"52","author":"Smith","year":"2009","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.heliyon.2025.e41980_bib56","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/d41587-020-00003-1","article-title":"Coronavirus puts drug repurposing on the fast track","volume":"38","author":"Harrison","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.heliyon.2025.e41980_bib57","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ejps.2017.05.009","article-title":"Intestinal absorption mechanisms of 2\u2032-deoxy-2\u2032-\u03b2-fluoro-4\u2032-azidocytidine, a cytidine analog for AIDS treatment, and its interaction with P-glycoprotein, multidrug resistance-associated protein 2 and breast cancer resistance protein","volume":"105","author":"Liu","year":"2017","journal-title":"Eur. J. Pharmaceut. Sci."},{"key":"10.1016\/j.heliyon.2025.e41980_bib58","doi-asserted-by":"crossref","DOI":"10.1038\/d41586-022-02050-x","article-title":"China approves first homegrown COVID antiviral","author":"Ye","year":"2022","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.heliyon.2025.e41980_bib59","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s12879-023-08828-2","article-title":"Azvudine versus paxlovid for oral treatment of COVID-19 in Chinese patients","volume":"24","author":"Su","year":"2024","journal-title":"BMC Infect. Dis."},{"issue":"3","key":"10.1016\/j.heliyon.2025.e41980_bib61","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1056\/NEJMoa2301425","article-title":"Oral Simnotrelvir for adult patients with mild-to-moderate covid-19","volume":"390","author":"Cao","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.heliyon.2025.e41980_bib62","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1021\/acsptsci.3c00134","article-title":"Deuremidevir and simnotrelvir-ritonavir for the treatment of COVID-19","volume":"6","author":"Zhu","year":"2023","journal-title":"ACS Pharmacol. Transl. Sci."},{"issue":"11","key":"10.1016\/j.heliyon.2025.e41980_bib63","doi-asserted-by":"crossref","DOI":"10.1038\/s41422-021-00570-1","article-title":"Design and development of an oral remdesivir derivative VV116 against SARS-CoV-2","volume":"31","author":"Xie","year":"2021","journal-title":"Cell Res."},{"issue":"2","key":"10.1016\/j.heliyon.2025.e41980_bib64","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S1473-3099(23)00577-7","article-title":"Oral VV116 versus placebo in patients with mild-to-moderate COVID-19 in China: a multicentre, double-blind, phase 3, randomised controlled study","volume":"24","author":"Fan","year":"2024","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.heliyon.2025.e41980_bib66","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102189","article-title":"Antiviral efficacy of RAY1216 monotherapy and combination therapy with ritonavir in patients with COVID-19: a phase 2, single centre, randomised, double-blind, placebo-controlled trial","volume":"63","author":"Wang","year":"2023","journal-title":"EClinicalMedicine"},{"issue":"Jan","key":"10.1016\/j.heliyon.2025.e41980_bib67","article-title":"Leritrelvir for the treatment of mild or moderate COVID-19 without co-administered ritonavir: a multicentre randomised, double-blind, placebo-controlled phase 3 trial","volume":"67","author":"Zhan","year":"2024","journal-title":"eClinicalMedicine"},{"issue":"1","key":"10.1016\/j.heliyon.2025.e41980_bib69","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1038\/s41467-020-15562-9","article-title":"Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV","volume":"11","author":"Ou","year":"2020","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.heliyon.2025.e41980_bib70","doi-asserted-by":"crossref","first-page":"756","DOI":"10.3390\/microorganisms9040756","article-title":"A study of 3CLpros as promising targets against SARS-CoV and SARS-CoV-2","volume":"9","author":"Jo","year":"2021","journal-title":"Microorganisms"},{"issue":"1","key":"10.1016\/j.heliyon.2025.e41980_bib71","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s42003-020-01577-x","article-title":"Identification of 3-chymotrypsin like protease (3CLPro) inhibitors as potential anti-SARS-CoV-2 agents","volume":"4","author":"Mody","year":"2021","journal-title":"Commun. Biol."},{"key":"10.1016\/j.heliyon.2025.e41980_bib72","series-title":"SAR and QSAR in Environmental Research","article-title":"Exploring RdRp\u2013remdesivir interactions to screen RdRp inhibitors for the management of novel coronavirus 2019-nCoV","author":"Singh","year":"2020"},{"key":"10.1016\/j.heliyon.2025.e41980_bib73","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2021.131756","article-title":"RdRp (RNA-dependent RNA polymerase): a key target providing anti-virals for the management of various viral diseases","volume":"1250","author":"Pathania","year":"2022","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.heliyon.2025.e41980_bib74","unstructured":"\u201cComparative docking of SARS-CoV-2 receptors antagonists from repurposing drugs | Physical Chemistry | ChemRxiv | Cambridge Open Engage.\u201d Accessed: November. 3, 2023. [Online]. Available: https:\/\/chemrxiv.org\/engage\/chemrxiv\/article-details\/60c75945469df4cbd8f4582b."},{"issue":"13","key":"10.1016\/j.heliyon.2025.e41980_bib75","doi-asserted-by":"crossref","first-page":"4594","DOI":"10.1080\/07391102.2020.1778537","article-title":"\u201cEthnomedicines of Indian origin for combating COVID-19 infection by hampering the viral replication: using structure-based drug discovery approach,\u201d","volume":"39","author":"S. Alagu Lakshmi, R. M. B. Shafreen, A. Priya, and K. P. Shunmugiah","year":"2021","journal-title":"J. Biomol. Struct. Dyn."},{"issue":"9","key":"10.1016\/j.heliyon.2025.e41980_bib76","first-page":"3263","article-title":"\u201cIn silico study the inhibition of angiotensin converting enzyme 2 receptor of COVID-19 by Ammoides verticillata components harvested from Western Algeria,\u201d","volume":"39","author":"Abdelli","year":"2021","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.heliyon.2025.e41980_bib77","article-title":"\u201cIn-Silico identification of potent inhibitors of COVID-19 main protease (Mpro) and angiotensin converting enzyme 2 (ACE2) from natural Products","author":"Omar","year":"2020","journal-title":"Quercetin, Hispidulin, and Cirsimaritin Exhibited Better Potential Inhibition than Hydroxy-Chloroquine Against COVID-19 Main Protease Active Site and ACE2,\u201d"},{"key":"10.1016\/j.heliyon.2025.e41980_bib78","series-title":"ACE2 Enzyme and S Protein Simple Peptide Sequence","article-title":"\u201cIn search for effective and safe drugs against SARS-CoV-2: Part I] simulated interactions between selected nutraceuticals","author":"Abdel-Mottaleb","year":"2020"},{"key":"10.1016\/j.heliyon.2025.e41980_bib79","article-title":"Repurposing therapeutics for COVID-19: supercomputer-based docking to the SARS-CoV-2 viral spike protein and viral spike protein-human ACE2 interface","author":"Smith","year":"2020","journal-title":"ChemRxiv"},{"issue":"5","key":"10.1016\/j.heliyon.2025.e41980_bib80","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.apsb.2020.02.008","article-title":"Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods","volume":"10","author":"Wu","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.heliyon.2025.e41980_bib81","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.3389\/fimmu.2020.01664","article-title":"Identification of SARS-CoV-2 cell entry inhibitors by drug repurposing using in silico structure-based virtual screening approach","volume":"11","author":"Choudhary","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.heliyon.2025.e41980_bib82","unstructured":"\u201cScreening of Clinically Approved and Investigation Drugs as Potential Inhibitors of SARS-CoV-2 Main Protease and Spike Receptor-Binding Domain Bound with ACE2 COVID19 Target Proteins: A Virtual Drug Repurposing Study | Theoretical and Computational Chemistry | ChemRxiv | Cambridge Open Engage.\u201d Accessed: November. 3, 2023. [Online]. Available: https:\/\/chemrxiv.org\/engage\/chemrxiv\/article-details\/60c74aa5702a9b4c1c18b2d4."},{"key":"10.1016\/j.heliyon.2025.e41980_bib83","doi-asserted-by":"crossref","unstructured":"A. Patel, M. Rajendran, A. Shah, H. Patel, S. B. Pakala, and P. Karyala, \u201cVirtual screening of curcumin and its analogs against the spike surface glycoprotein of SARS-CoV-2 and SARS-CoV,\u201d J. Biomol. Struct. Dyn., pp. 1\u20139, doi: 10.1080\/07391102.2020.1868338.","DOI":"10.1080\/07391102.2020.1868338"},{"key":"10.1016\/j.heliyon.2025.e41980_bib84","unstructured":"\u201cExploring the Active Compounds of Traditional Mongolian Medicine Agsirga in Intervention of Novel Coronavirus (2019-nCoV) Based on HPLC-Q-Exactive-MS\/MS and Molecular Docking Method | Biological and Medicinal Chemistry | ChemRxiv | Cambridge Open Engage.\u201d Accessed: November. 3, 2023. [Online]. Available: https:\/\/chemrxiv.org\/engage\/chemrxiv\/article-details\/60c748c6bb8c1a5ad13dad25."},{"key":"10.1016\/j.heliyon.2025.e41980_bib85","article-title":"Darunavir disrupts critical nodes in metastable 2019-nCoV-RBD\/ACE-2 complex","author":"Omotuyi","year":"2020","journal-title":"Preprints"},{"key":"10.1016\/j.heliyon.2025.e41980_bib86","unstructured":"\u201cThe interaction of the severe acute respiratory syndrome coronavi.: Ingenta Connect.\u201d Accessed: November. 3, 2023. [Online]. Available: https:\/\/www.ingentaconnect.com\/content\/wk\/jhype\/2021\/00000039\/00000008\/art00027."},{"issue":"14","key":"10.1016\/j.heliyon.2025.e41980_bib87","doi-asserted-by":"crossref","first-page":"5033","DOI":"10.1080\/07391102.2020.1784289","article-title":"In-silico investigation of phytochemicals from Asparagus racemosus as plausible antiviral agent in COVID-19","volume":"39","author":"Chikhale","year":"2021","journal-title":"J. Biomol. Struct. Dyn."},{"issue":"12","key":"10.1016\/j.heliyon.2025.e41980_bib88","doi-asserted-by":"crossref","first-page":"4510","DOI":"10.1080\/07391102.2020.1778539","article-title":"Sars-cov-2 host entry and replication inhibitors from Indian ginseng: an in-silico approach","volume":"39","author":"Chikhale","year":"2021","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.heliyon.2025.e41980_bib90","series-title":"Combined Use of Amentoflavone and Ledipasvir Could Interfere with Binding of Spike Glycoprotein of SARS-CoV-2 to ACE2: the Results of Molecular Docking Stud","author":"Miroshnychenko","year":"2020"},{"issue":"9","key":"10.1016\/j.heliyon.2025.e41980_bib91","first-page":"3225","article-title":"Stilbene-based natural compounds as promising drug candidates against COVID-19","volume":"39","author":"Wahedi","year":"2021","journal-title":"J. Biomol. Struct. Dyn."},{"issue":"7909","key":"10.1016\/j.heliyon.2025.e41980_bib92","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-022-04661-w","article-title":"A TMPRSS2 inhibitor acts as a pan-SARS-CoV-2 prophylactic and therapeutic","volume":"605","author":"Shapira","year":"2022","journal-title":"Nature"},{"issue":"43","key":"10.1016\/j.heliyon.2025.e41980_bib93","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2108728118","article-title":"A novel class of TMPRSS2 inhibitors potently block SARS-CoV-2 and MERS-CoV viral entry and protect human epithelial lung cells","volume":"118","author":"Mahoney","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"33","key":"10.1016\/j.heliyon.2025.e41980_bib94","doi-asserted-by":"crossref","first-page":"11876","DOI":"10.1073\/pnas.0505577102","article-title":"Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry","volume":"102","author":"Simmons","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1","key":"10.1016\/j.heliyon.2025.e41980_bib95","doi-asserted-by":"crossref","DOI":"10.1038\/s41392-021-00558-8","article-title":"Cathepsin L plays a key role in SARS-CoV-2 infection in humans and humanized mice and is a promising target for new drug development","volume":"6","author":"Zhao","year":"2021","journal-title":"Sig Transduct Target Ther"},{"issue":"2","key":"10.1016\/j.heliyon.2025.e41980_bib96","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.108254","article-title":"Furin inhibitors block SARS-CoV-2 spike protein cleavage to suppress virus production and cytopathic effects","volume":"33","author":"Cheng","year":"2020","journal-title":"Cell Rep."},{"issue":"5","key":"10.1016\/j.heliyon.2025.e41980_bib97","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1007\/s11845-021-02820-y","article-title":"Sars-Cov-2 and risk of antiviral drug resistance","volume":"191","author":"Vitiello","year":"2022","journal-title":"Ir. J. Med. Sci."},{"issue":"2","key":"10.1016\/j.heliyon.2025.e41980_bib98","doi-asserted-by":"crossref","first-page":"taaa021","DOI":"10.1093\/jtm\/taaa021","article-title":"The reproductive number of COVID-19 is higher compared to SARS coronavirus","volume":"27","author":"Liu","year":"2020","journal-title":"J. Trav. Med."},{"issue":"6531","key":"10.1016\/j.heliyon.2025.e41980_bib99","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1126\/science.abf9302","article-title":"Prospective mapping of viral mutations that escape antibodies used to treat COVID-19","volume":"371","author":"Starr","year":"2021","journal-title":"Science"},{"issue":"7857","key":"10.1016\/j.heliyon.2025.e41980_bib100","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/s41586-021-03398-2","article-title":"Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7","volume":"593","author":"Wang","year":"2021","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.heliyon.2025.e41980_bib101","doi-asserted-by":"crossref","DOI":"10.26508\/lsa.202101049","article-title":"Incomplete antiviral treatment may induce longer durations of viral shedding during SARS-CoV-2 infection","volume":"4","author":"Kim","year":"2021","journal-title":"Life Sci. Alliance"},{"key":"10.1016\/j.heliyon.2025.e41980_bib102","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.801522","article-title":"A detailed overview of immune escape, antibody escape, partial vaccine escape of SARS-CoV-2 and their emerging variants with escape mutations","volume":"13","author":"Chakraborty","year":"2022","journal-title":"Front. Immunol."},{"issue":"S18","key":"10.1016\/j.heliyon.2025.e41980_bib103","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1186\/s12859-020-03825-7","article-title":"Evolution of drug resistance in HIV protease","volume":"21","author":"Shah","year":"2020","journal-title":"BMC Bioinf."},{"issue":"11","key":"10.1016\/j.heliyon.2025.e41980_bib104","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1080\/23744235.2023.2238077","article-title":"Combination of two rare mutations in the SARS-CoV-2 M gene in patients with severe and prolonged COVID-19","volume":"55","author":"Trifonova","year":"2023","journal-title":"Infectious Diseases"},{"issue":"7","key":"10.1016\/j.heliyon.2025.e41980_bib106","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.1172\/JCI136225","article-title":"Herpesvirus latency","volume":"130","author":"Cohen","year":"2020","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.heliyon.2025.e41980_bib107","series-title":"HIV Integration","year":"2023"},{"issue":"10","key":"10.1016\/j.heliyon.2025.e41980_bib108","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1008271","article-title":"Viral quasispecies","volume":"15","author":"Domingo","year":"2019","journal-title":"PLoS Genet."},{"issue":"1","key":"10.1016\/j.heliyon.2025.e41980_bib109","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/nyas.12462","article-title":"Continuing challenges in influenza","volume":"1323","author":"Webster","year":"2014","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.heliyon.2025.e41980_bib110","series-title":"Genetics and Evolution of Infectious Disease","first-page":"339","article-title":"General mechanisms of antiviral resistance","author":"Vere Hodge","year":"2011"},{"issue":"12","key":"10.1016\/j.heliyon.2025.e41980_bib111","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.tim.2003.10.006","article-title":"Error thresholds and the constraints to RNA virus evolution","volume":"11","author":"Holmes","year":"2003","journal-title":"Trends Microbiol."},{"issue":"6","key":"10.1016\/j.heliyon.2025.e41980_bib112","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.coviro.2011.09.002","article-title":"Antivirals and resistance: influenza virus","volume":"1","year":"2011","journal-title":"Current Opinion in Virology"},{"issue":"2","key":"10.1016\/j.heliyon.2025.e41980_bib113","first-page":"413","article-title":"Antiviral drug resistance: mechanisms and clinical implications","volume":"24","author":"Strasfeld","year":"2010","journal-title":"Infect. Dis. Clin."},{"issue":"1","key":"10.1016\/j.heliyon.2025.e41980_bib114","doi-asserted-by":"crossref","first-page":"vew014","DOI":"10.1093\/ve\/vew014","article-title":"Antiviral drug resistance as an adaptive process","volume":"2","author":"Irwin","year":"2016","journal-title":"Virus Evolution"},{"issue":"19","key":"10.1016\/j.heliyon.2025.e41980_bib115","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2100425118","article-title":"Dual nature of human ACE2 glycosylation in binding to SARS-CoV-2 spike","volume":"118","author":"Mehdipour","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1","key":"10.1016\/j.heliyon.2025.e41980_bib116","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-021-00809-8","article-title":"The glycosylation in SARS-CoV-2 and its receptor ACE2","volume":"6","author":"Gong","year":"2021","journal-title":"Sig Transduct Target Ther"},{"key":"10.1016\/j.heliyon.2025.e41980_bib117","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.61552","article-title":"Inhibition of SARS-CoV-2 viral entry upon blocking N- and O-glycan elaboration","volume":"9","author":"Yang","year":"2020","journal-title":"Elife"},{"issue":"9","key":"10.1016\/j.heliyon.2025.e41980_bib118","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1009929","article-title":"In vitro selection of Remdesivir resistance suggests evolutionary predictability of SARS-CoV-2","volume":"17","author":"Szemiel","year":"2021","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.heliyon.2025.e41980_bib119","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1038\/s41467-022-29104-y","article-title":"De novo emergence of a remdesivir resistance mutation during treatment of persistent SARS-CoV-2 infection in an immunocompromised patient: a case report","volume":"13","author":"Gandhi","year":"2022","journal-title":"Nat. Commun."},{"issue":"656","key":"10.1016\/j.heliyon.2025.e41980_bib120","doi-asserted-by":"crossref","first-page":"eabo0718","DOI":"10.1126\/scitranslmed.abo0718","article-title":"Mutations in the SARS-CoV-2 RNA-dependent RNA polymerase confer resistance to remdesivir by distinct mechanisms","volume":"14","author":"Stevens","year":"2022","journal-title":"Sci. Transl. Med."},{"issue":"43","key":"10.1016\/j.heliyon.2025.e41980_bib121","doi-asserted-by":"crossref","first-page":"26946","DOI":"10.1073\/pnas.2012294117","article-title":"Remdesivir targets a structurally analogous region of the Ebola virus and SARS-CoV-2 polymerases","volume":"117","author":"Lo","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"1","key":"10.1016\/j.heliyon.2025.e41980_bib122","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2020.101992","article-title":"High-throughput rational design of the remdesivir binding site in the RdRp of SARS-CoV-2: implications for potential resistance","volume":"24","author":"Padhi","year":"2020","journal-title":"iScience"},{"key":"10.1016\/j.heliyon.2025.e41980_bib123","doi-asserted-by":"crossref","first-page":"3604","DOI":"10.1038\/s41467-024-47941-x","article-title":"Dynamic diversity of SARS-CoV-2 genetic mutations in a lung transplantation patient with persistent COVID-19","volume":"15","author":"Igari","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.heliyon.2025.e41980_bib124","unstructured":"Interface\u2010based design of the favipiravir\u2010binding site in SARS\u2010CoV\u20102 RNA\u2010dependent RNA polymerase reveals mutations conferring resistance to chain termination - PMC.\u201d Accessed: Aug. 06, 2024. [Online]. Available: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC8426738\/."},{"issue":"7944","key":"10.1016\/j.heliyon.2025.e41980_bib125","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-022-05514-2","article-title":"Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir","volume":"613","author":"Iketani","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.heliyon.2025.e41980_bib126","article-title":"Naturally occurring mutations of SARS-CoV-2 main protease confer drug resistance to nirmatrelvir","author":"Hu","year":"2022","journal-title":"bioRxiv"},{"issue":"51","key":"10.1016\/j.heliyon.2025.e41980_bib128","doi-asserted-by":"crossref","first-page":"eadd7197","DOI":"10.1126\/sciadv.add7197","article-title":"Nirmatrelvir-resistant SARS-CoV-2 variants with high fitness in an infectious cell culture system","volume":"8","author":"Zhou","year":"2022","journal-title":"Sci. Adv."},{"key":"10.1016\/j.heliyon.2025.e41980_bib129","unstructured":"\u201cNirmatrelvir-resistant SARS-CoV-2 is efficiently transmitted in Syrian hamsters | bioRxiv.\u201d Accessed: December. 5, 2023. [Online]. Available: https:\/\/www.biorxiv.org\/content\/10.1101\/2022.09.28.509903v1.abstract."},{"key":"10.1016\/j.heliyon.2025.e41980_bib130","first-page":"ciad494","article-title":"Nirmatrelvir resistance\u2014de Novo E166V\/L50V mutations in an immunocompromised patient treated with prolonged nirmatrelvir\/ritonavir monotherapy leading to clinical and virological treatment failure\u2014a case report","author":"Zuckerman","year":"2023","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.heliyon.2025.e41980_bib131","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104559","article-title":"Global prevalence of SARS-CoV-2 3CL protease mutations associated with nirmatrelvir or ensitrelvir resistance","volume":"91","author":"Ip","year":"2023","journal-title":"EBioMedicine"},{"issue":"5","key":"10.1016\/j.heliyon.2025.e41980_bib132","doi-asserted-by":"crossref","DOI":"10.3390\/v16050718","article-title":"Nirmatrelvir resistance in an immunocompromised patient with persistent coronavirus disease 2019","volume":"16","author":"Yamamoto","year":"2024","journal-title":"Viruses"},{"key":"10.1016\/j.heliyon.2025.e41980_bib133","series-title":"Transmissible SARS-CoV-2 Variants with Resistance to Clinical Protease Inhibitors","author":"Moghadasi","year":"2022"},{"issue":"1","key":"10.1016\/j.heliyon.2025.e41980_bib134","article-title":"In vitro and in vivo characterization of SARS-CoV-2 resistance to ensitrelvir","volume":"14","author":"Kiso","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.heliyon.2025.e41980_bib135","unstructured":"Hotspot residues and resistance mutations in the nirmatrelvir-binding site of SARS-CoV-2 main protease: Design, identification, and correlation with globally circulating viral genomes - PMC.\u201d Accessed: Aug. 06, 2024. [Online]. Available: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC9450486\/."},{"issue":"11","key":"10.1016\/j.heliyon.2025.e41980_bib136","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.medj.2023.08.001","article-title":"Multidrug-resistant mutations to antiviral and antibody therapy in an immunocompromised patient infected with SARS-CoV-2","volume":"4","author":"Hirotsu","year":"2023","journal-title":"Med"},{"issue":"4","key":"10.1016\/j.heliyon.2025.e41980_bib137","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1021\/acsinfecdis.3c00560","article-title":"Contributions of hyperactive mutations in Mpro from SARS-CoV-2 to drug resistance","volume":"10","author":"Flynn","year":"2024","journal-title":"ACS Infect. Dis."},{"issue":"1","key":"10.1016\/j.heliyon.2025.e41980_bib139","doi-asserted-by":"crossref","DOI":"10.1080\/22221751.2023.2212806","article-title":"Post-exposure prophylaxis with SA58 (anti-SARS-COV-2 monoclonal antibody) nasal spray for the prevention of symptomatic COVID-19 in healthy adult workers: a randomized, single-blind, placebo-controlled clinical study","volume":"12","author":"Song","year":"2023","journal-title":"Emerg Microbes Infect"},{"key":"10.1016\/j.heliyon.2025.e41980_bib140","unstructured":"\u201cIntranasal trimeric sherpabody inhibits SARS-CoV-2 including recent immunoevasive Omicron subvariants | Nat. Commun.\u201d Accessed: January. 2, 2024. [Online]. Available: https:\/\/www.nature.com\/articles\/s41467-023-37290-6."},{"key":"10.1016\/j.heliyon.2025.e41980_bib141","article-title":"Therapeutic and vaccine-induced cross-reactive antibodies with effector function against emerging Omicron variants","author":"Addetia","year":"2023","journal-title":"bioRxiv"},{"issue":"1","key":"10.1016\/j.heliyon.2025.e41980_bib142","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-31615-7","article-title":"Resilience of S309 and AZD7442 monoclonal antibody treatments against infection by SARS-CoV-2 Omicron lineage strains","volume":"13","author":"Case","year":"2022","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.heliyon.2025.e41980_bib143","doi-asserted-by":"crossref","first-page":"765","DOI":"10.3390\/v15030765","article-title":"Convalescent plasma therapy for COVID-19: a systematic review and meta-analysis on randomized controlled trials","volume":"15","author":"Filippatos","year":"2023","journal-title":"Viruses"},{"issue":"6","key":"10.1016\/j.heliyon.2025.e41980_bib144","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.chom.2020.05.008","article-title":"Type I and type III interferons - induction, signaling, evasion, and application to combat COVID-19","volume":"27","author":"Park","year":"2020","journal-title":"Cell Host Microbe"},{"issue":"7","key":"10.1016\/j.heliyon.2025.e41980_bib145","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1008737","article-title":"Interplay between SARS-CoV-2 and the type I interferon response","volume":"16","author":"Sa Ribero","year":"2020","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.heliyon.2025.e41980_bib146","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2023.1198576","article-title":"Interferons in COVID-19: missed opportunities to prove efficacy in clinical phase III trials?","volume":"10","author":"Brzoska","year":"2023","journal-title":"Front. Med."},{"key":"10.1016\/j.heliyon.2025.e41980_bib147","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1007955","article-title":"A GABA-receptor agonist reduces pneumonitis severity, viral load, and death rate in SARS-CoV-2-infected mice","volume":"13","author":"Tian","year":"2022","journal-title":"Front. Immunol."},{"issue":"661","key":"10.1016\/j.heliyon.2025.e41980_bib148","doi-asserted-by":"crossref","first-page":"eabm7621","DOI":"10.1126\/scitranslmed.abm7621","article-title":"The adenosine analog prodrug ATV006 is orally bioavailable and has preclinical efficacy against parental SARS-CoV-2 and variants","volume":"14","author":"Cao","year":"2022","journal-title":"Sci. Transl. Med."},{"issue":"6","key":"10.1016\/j.heliyon.2025.e41980_bib149","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1016\/j.apsb.2021.03.028","article-title":"Can remdesivir and its parent nucleoside GS-441524 be potential oral drugs? An in vitro and in vivo DMPK assessment","volume":"11","author":"Xie","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"issue":"643","key":"10.1016\/j.heliyon.2025.e41980_bib150","doi-asserted-by":"crossref","first-page":"eabm3410","DOI":"10.1126\/scitranslmed.abm3410","article-title":"Therapeutic treatment with an oral prodrug of the remdesivir parental nucleoside is protective against SARS-CoV-2 pathogenesis in mice","volume":"14","author":"Sch\u00e4fer","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.heliyon.2025.e41980_bib151","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1054962","article-title":"Cellular stress modulates severity of the inflammatory response in lungs via cell surface BiP","volume":"13","author":"Rico-Llanos","year":"2022","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.heliyon.2025.e41980_bib152","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1186\/s40001-022-00818-5","article-title":"Traditional herbs against COVID-19: back to old weapons to combat the new pandemic","volume":"27","author":"Al-kuraishy","year":"2022","journal-title":"Eur. J. Med. Res."},{"key":"10.1016\/j.heliyon.2025.e41980_bib153","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.104761","article-title":"Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2)","volume":"156","author":"Runfeng","year":"2020","journal-title":"Pharmacol. Res."},{"issue":"1","key":"10.1016\/j.heliyon.2025.e41980_bib154","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.joim.2021.10.005","article-title":"Meta-analysis on the effect of combining Lianhua Qingwen with Western medicine to treat coronavirus disease 2019","volume":"20","author":"Wang","year":"2022","journal-title":"J Integr Med"},{"issue":"16","key":"10.1016\/j.heliyon.2025.e41980_bib155","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.7150\/ijms.46378","article-title":"Investigating the mechanism of ShuFeng JieDu capsule for the treatment of novel Coronavirus pneumonia (COVID-19) based on network pharmacology","volume":"17","author":"Chen","year":"2020","journal-title":"Int. J. Med. Sci."},{"key":"10.1016\/j.heliyon.2025.e41980_bib156","doi-asserted-by":"crossref","unstructured":"D. K. Maurya and D. Sharma, \u201cEvaluation of traditional ayurvedic Kadha for prevention and management of the novel Coronavirus (SARS-CoV-2) using in silico approach,\u201d J. Biomol. Struct. Dyn., pp. 1\u201316, doi: 10.1080\/07391102.2020.1852119.","DOI":"10.1080\/07391102.2020.1852119"},{"issue":"2","key":"10.1016\/j.heliyon.2025.e41980_bib157","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s10787-022-00939-7","article-title":"Advancing combination treatment with glycyrrhizin and boswellic acids for hospitalized patients with moderate COVID-19 infection: a randomized clinical trial","volume":"30","author":"Gomaa","year":"2022","journal-title":"Inflammopharmacology"},{"issue":"4","key":"10.1016\/j.heliyon.2025.e41980_bib158","doi-asserted-by":"crossref","DOI":"10.30848\/PJB2022-4(44)","article-title":"Plants secondary metabolites (PSMS), as an investigational source against COVID-19 from flora of Pakistan","volume":"54","author":"Khan","year":"2022","journal-title":"PAK. J. BOT."},{"issue":"7","key":"10.1016\/j.heliyon.2025.e41980_bib159","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1002\/ptr.7442","article-title":"The naturally-derived alkaloids as a potential treatment for COVID-19: a scoping review","volume":"36","author":"Gonzalez","year":"2022","journal-title":"Phytother Res."},{"issue":"4","key":"10.1016\/j.heliyon.2025.e41980_bib160","first-page":"58","article-title":"Optimisation of Vitamin D status for enhanced immuno-protection against covid-19","volume":"113","author":"McCartney","year":"2020","journal-title":"Ir. Med. J."},{"key":"10.1016\/j.heliyon.2025.e41980_bib161","article-title":"Vitamin C as prophylaxis and adjunctive medical treatment for COVID-19?","volume":"79\u201380","author":"Feyaerts","year":"2020","journal-title":"Nutrition"},{"issue":"3","key":"10.1016\/j.heliyon.2025.e41980_bib163","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1080\/09537104.2020.1742311","article-title":"Zinc regulates reactive oxygen species generation in platelets","volume":"32","author":"Lopes-Pires","year":"2021","journal-title":"Platelets"},{"issue":"4","key":"10.1016\/j.heliyon.2025.e41980_bib164","doi-asserted-by":"crossref","first-page":"478","DOI":"10.3947\/ic.2020.52.4.478","article-title":"Omega 3 fatty acids and COVID-19: a comprehensive review","volume":"52","author":"Hathaway","year":"2020","journal-title":"Infect Chemother"},{"key":"10.1016\/j.heliyon.2025.e41980_bib165","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1138215","article-title":"Pharmacological potential of Withania somnifera (L.) Dunal and Tinospora cordifolia (Willd.) Miers on the experimental models of COVID-19, T cell differentiation, and neutrophil functions","volume":"14","author":"Rizvi","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.heliyon.2025.e41980_bib166","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2022.105430","article-title":"Combination therapy with nirmatrelvir and molnupiravir improves the survival of SARS-CoV-2 infected mice","volume":"208","author":"Jeong","year":"2022","journal-title":"Antiviral Res"},{"issue":"09.03.506479","key":"10.1016\/j.heliyon.2025.e41980_bib167","first-page":"2022","article-title":"Combined molnupiravir and nirmatrelvir treatment improves the inhibitory effect on SARS-CoV-2 in rhesus macaques","author":"Rosenke","year":"2022","journal-title":"bioRxiv"},{"key":"10.1016\/j.heliyon.2025.e41980_bib168","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ijid.2023.04.412","article-title":"Combination regimen of nirmatrelvir\/ritonavir and molnupiravir for the treatment of persistent SARS-CoV-2 infection: a case report and a scoping review of the literature","volume":"133","author":"Marangoni","year":"2023","journal-title":"Int. J. Infect. Dis."},{"issue":"7","key":"10.1016\/j.heliyon.2025.e41980_bib169","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.3390\/microorganisms10071475","article-title":"The combination of molnupiravir with nirmatrelvir or GC376 has a synergic role in the inhibition of SARS-CoV-2 replication in vitro","volume":"10","author":"Gidari","year":"2022","journal-title":"Microorganisms"},{"issue":"5","key":"10.1016\/j.heliyon.2025.e41980_bib170","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.3390\/v15051175","article-title":"Combination therapy with UV-4B and molnupiravir enhances SARS-CoV-2 suppression","volume":"15","author":"Franco","year":"2023","journal-title":"Viruses"},{"key":"10.1016\/j.heliyon.2025.e41980_bib171","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103595","article-title":"The combined treatment of Molnupiravir and Favipiravir results in a potentiation of antiviral efficacy in a SARS-CoV-2 hamster infection model","volume":"72","author":"Abdelnabi","year":"2021","journal-title":"EBioMedicine"},{"issue":"2","key":"10.1016\/j.heliyon.2025.e41980_bib172","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1093\/cid\/ciad181","article-title":"Triple combination therapy with 2 antivirals and monoclonal antibodies for persistent or relapsed severe acute respiratory syndrome coronavirus 2 infection in immunocompromised patients","volume":"77","author":"Mikulska","year":"2023","journal-title":"Clin. Infect. Dis."},{"issue":"5","key":"10.1016\/j.heliyon.2025.e41980_bib173","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1002\/hon.3206","article-title":"Dual combined antiviral treatment with remdesivir and nirmatrelvir\/ritonavir in patients with impaired humoral immunity and persistent SARS-CoV-2 infection","volume":"41","author":"Pasquini","year":"2023","journal-title":"Hematol. Oncol."},{"key":"10.1016\/j.heliyon.2025.e41980_bib174","unstructured":"\u201cPyrimidine inhibitors synergize with nucleoside analogues to block SARS-CoV-2 | Nature.\u201d Accessed: February. 27, 2024. [Online]. Available: https:\/\/www.nature.com\/articles\/s41586-022-04482-x."},{"issue":"5","key":"10.1016\/j.heliyon.2025.e41980_bib175","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1093\/cid\/ciac847","article-title":"Dual antiviral therapy for persistent coronavirus disease 2019 and associated organizing pneumonia in an immunocompromised host","volume":"76","author":"Trottier","year":"2023","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.heliyon.2025.e41980_bib176","doi-asserted-by":"crossref","unstructured":"\u201cSuccessful Combination Treatment for Persistent Severe Acute Respiratory Syndrome Coronavirus 2 Infection | Clin. Infect. Dis. | Oxford Academic.\u201d Accessed: February. 27, 2024. [Online]. Available: https:\/\/academic.oup.com\/cid\/article\/76\/10\/1864\/7035946.","DOI":"10.1093\/cid\/ciad085"},{"key":"10.1016\/j.heliyon.2025.e41980_bib178","doi-asserted-by":"crossref","DOI":"10.54034\/mic.e1366","article-title":"Molnupiravir in combination with remdesivir for severe COVID-19 patients admitted to hospital: a case series","volume":"2","author":"Hashemian","year":"2022","journal-title":"Microbes, Infection and Chemotherapy"},{"key":"10.1016\/j.heliyon.2025.e41980_bib179","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.1072202","article-title":"Combination of the parent analogue of remdesivir (GS-441524) and molnupiravir results in a markedly potent antiviral effect in SARS-CoV-2 infected Syrian hamsters","volume":"13","author":"Abdelnabi","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"Jan","key":"10.1016\/j.heliyon.2025.e41980_bib180","article-title":"Combination therapy with oral antiviral and anti-inflammatory drugs improves the efficacy of delayed treatment in a COVID-19 hamster model","volume":"99","author":"Sasaki","year":"2024","journal-title":"EBioMedicine"},{"key":"10.1016\/j.heliyon.2025.e41980_bib181","first-page":"1","article-title":"Virtual screening and dynamics of potential inhibitors targeting RNA binding domain of nucleocapsid phosphoprotein from SARS-CoV-2","author":"Yadav","year":"2020","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.heliyon.2025.e41980_bib182","doi-asserted-by":"crossref","unstructured":"A. O. Fadaka, R. T. Aruleba, N. R. S. Sibuyi, A. Klein, A. M. Madiehe, and M. Meyer, \u201cInhibitory potential of repurposed drugs against the SARS-CoV-2 main protease: a computational-aided approach,\u201d J. Biomol. Struct. Dyn., pp. 1\u201313, doi: 10.1080\/07391102.2020.1847197.","DOI":"10.1080\/07391102.2020.1847197"},{"key":"10.1016\/j.heliyon.2025.e41980_bib183","doi-asserted-by":"crossref","unstructured":"R. K. Saxena et al., \u201cAssessment of prevalence of SARS-CoV-2 Infection in patients on anti-HBV (lamivudine) treatment: a questionnaire based survey,\u201d IP International Journal of Medical Microbiology and Tropical Diseases, vol. 7, no. 1, pp. 17\u201323, doi: 10.18231\/j.ijmmtd.2021.005.","DOI":"10.18231\/j.ijmmtd.2021.005"},{"issue":"11","key":"10.1016\/j.heliyon.2025.e41980_bib184","doi-asserted-by":"crossref","first-page":"4690","DOI":"10.1021\/acs.jproteome.0c00392","article-title":"Nucleotide analogues as inhibitors of SARS-CoV-2 polymerase, a key drug target for COVID-19","volume":"19","author":"Chien","year":"2020","journal-title":"J. Proteome Res."},{"key":"10.1016\/j.heliyon.2025.e41980_bib185","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.100993","article-title":"Effect of Tenofovir Disoproxil Fumarate and Emtricitabine on nasopharyngeal SARS-CoV-2 viral load burden amongst outpatients with COVID-19: a pilot, randomized, open-label phase 2 trial","volume":"38","author":"Parienti","year":"2021","journal-title":"EClinicalMedicine"},{"issue":"1","key":"10.1016\/j.heliyon.2025.e41980_bib186","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: progress, challenges and recommendations","volume":"18","author":"Pushpakom","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"issue":"612","key":"10.1016\/j.heliyon.2025.e41980_bib187","doi-asserted-by":"crossref","first-page":"eabd5524","DOI":"10.1126\/scitranslmed.abd5524","article-title":"Drug repurposing: misconceptions, challenges, and opportunities for academic researchers","volume":"13","author":"Begley","year":"2021","journal-title":"Sci. Transl. Med."},{"issue":"7","key":"10.1016\/j.heliyon.2025.e41980_bib188","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/s41573-023-00692-8","article-title":"Accelerating antiviral drug discovery: lessons from COVID-19","volume":"22","author":"Von Delft","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"issue":"12","key":"10.1016\/j.heliyon.2025.e41980_bib189","doi-asserted-by":"crossref","first-page":"4017","DOI":"10.1021\/acssensors.0c01929","article-title":"Colorimetric detection of SARS-CoV-2 and drug-resistant pH1N1 using CRISPR\/dCas9","volume":"5","author":"Moon","year":"2020","journal-title":"ACS Sens."},{"key":"10.1016\/j.heliyon.2025.e41980_bib190","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcv.2022.105323","article-title":"Sierra SARS-CoV-2 sequence and antiviral resistance analysis program","volume":"157","author":"Tzou","year":"2022","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.heliyon.2025.e41980_bib191","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1186\/s12879-023-08236-6","article-title":"SABRes: in silico detection of drug resistance conferring mutations in subpopulations of SARS-CoV-2 genomes","volume":"23","author":"Fong","year":"2023","journal-title":"BMC Infect. Dis."},{"issue":"2","key":"10.1016\/j.heliyon.2025.e41980_bib192","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1128\/JCM.02016-06","article-title":"Evaluation of dried blood spots for human immunodeficiency virus type 1 drug resistance testing","volume":"45","author":"McNulty","year":"2007","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.heliyon.2025.e41980_bib194","unstructured":"\u201cMonitoring of SARS-CoV-2 antibodies using dried blood spot for at-home collection | Sci. Rep.\u201d Accessed: July. 31, 2024. [Online]. Available: https:\/\/www.nature.com\/articles\/s41598-022-09699-4."}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844025003603?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844025003603?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T22:33:22Z","timestamp":1769034802000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844025003603"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":177,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S2405844025003603"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2025.e41980","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SARS-CoV-2 drug resistance and therapeutic approaches","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2025.e41980","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e41980"}}